Inclusion Criteria:

          1. Newly histologically confirmed CD20 positive diffuse large B-cell lymphomas and only
             Non-GCB type will be included

          2. High intermediate or high risk by IPI risk, or Bulky mass ≥ 10cm at diagnosis

          3. Complete response is confirmed after six or eight cycles R-CHOP chemotherapy by CT
             scan with confirmed negative PET-CT based on the Revised International Workshop
             Criteria.

          4. Additional surgery or radiotherapy are accepted

          5. Age ≥ 20

          6. Performance status (ECOG) ≤ 2

          7. Adeqaute renal function: Cr < 2.5 mg/dL

          8. Adeqaute liver functions: Transaminase (AST/ALT) < 3 x upper normal value
             UNV)Bilirubin < 1.5 x UNV Alkaline phosphatase < 5 xUNV

          9. Adeqaute BM functions: ANC > 1,000/uL and platelet > 75,000/uL and hemoglobin > 9.0
             g/dL

         10. Written Informed consent

        Exclusion Criteria:

          1. Tumor response after 6-8 cycles CTx< CR

          2. Consider stem cell transplantation

          3. Central nervous system (CNS) metastases

          4. Pregnant or lactating women, patients of childbearing potential not employing adequate
             contraception

          5. Other serious illness or medical conditions A. Unstable cardiac disease despite
             treatment, myocardial infarction within 6 months prior to study entry B. History of
             significant neurologic or psychiatric disorders including dementia or seizures C.
             Active uncontrolled infection

          6. Any other malignancies within the past 5 years except curatively treated non- melanoma
             skin cancer or in situ carcinoma of cervix uteri.

          7. Prior history of allegic reaction to study treatment drugs

          8. Peripheral neuropathy grade 2 or worse

          9. DLBCL of the testis and primary mediastinal DLBCL